Science and technology company Merck has announced the expansion of its facility in Lenexa, Kansas, USA, adding 9,100 sq m2 of lab space and production capability to manufacture cell culture media.
A $76m investment in the facility in Grand Island, New York, will increase capacity to produce raw materials used in manufacture of vaccines and biologic therapies.
Fujifilm Irvine Scientific, Inc, is to build a new bioprocessing center in China, with the goal of ensuring local cell culture media optimization support for vaccines, advanced therapies, and biotherapeutic drug development.
Waters Corporation and Sartorius are partnering with the aim of providing bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.
Cytiva and Pall Corporation, both subsidiaries of Danaher Corporation, have announced they are to invest US$1.5bn to expand manufacturing capacity across 13 sites globally
By InVitria launches xeno-free service within $5.2bn media market
Xeno-free media will continue to increase its share of the estimated 30m litre mammalian cell culture market says InVitria, which has launched a new formulation service.
Sartorius Stedim Biotech (SSB) has cut its full year guidance, citing the negative impact of hurricane Maria, customer destocking and ongoing issues with a cell culture media supplier.
Janssen says culture media HyClone Laboratories makes for Celltrion infringe on a US patent covering broths used in the manufacture of Remicade (infliximab).
SAFC (Sigma-Aldrich Corporation) says it will invest across its life science businesses following a first quarter that saw “weak” contract manufacturing but flourishing viral and cell media sectors.
